Source: International Congress 2016 – Pulmonary drug delivery
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Jussi Haikarainen (Espoo, Finland), Jussi Haikarainen, Paula Rytilä, Sirpa Metsärinne, Anita Happonen. Budesonide-formoterol Easyhaler®: Dose consistency under simulated real-life conditions. Eur Respir J 2016; 48: Suppl. 60, 969

Member's Comments

No comment yet.

Related content which might interest you: Pressurized Metered Dose Inhaler (pMDI) - Correct procedure Source: Procedure Video 2018 Year: 2018 In vitro analysis of two formulations of fluticasone/ salmeterol pMDI for delivered dose uniformity and aerodynamic particle size distribution Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 Switch to Budesonide/Formoterol Easyhaler Inhalation from other inhalers in asthma patients; A real-life study Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies Year: 2018 High dose extrafine beclomethasone/formoterol via metered dose inhaler is effective and safe in asthmatics not controlled on medium-high dose of inhaled corticosteroids Source: International Congress 2014 – Asthma and COPD management Year: 2014 Pressurized Metered Dose Inhaler (pMDI) with holding chamber - Correct procedure Source: Procedure Video 2018 Year: 2018 Switch from Symbicort Turbuhaler to Bufomix Easyhaler; a real-life prospective study in asthma patients Source: International Congress 2018 – Clinical markers of asthma Year: 2018 In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Plume temperature and force of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Device handling study of a novel fluticasone propionate/formoterol breath-triggered inhaler Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Budesonide/formoterol in Turbuhaler© is not affected by storage in hot and humid conditions. A clinical pharmacokinetic comparison with fluticasone/salmeterol in DiskusÔ Source: Eur Respir J 2003; 22: Suppl. 45, 237s Year: 2003 Technique: the usual problem of metered dose inhalers Source: Eur Respir J 2002; 20: Suppl. 38, 503s Year: 2002 Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 311s Year: 2003 Critical handling errors with dry-powder, metered dose and soft-mist inhaler devices in an observational COPD study Source: International Congress 2019 – COPD treatment: clinical trials, cohorts and inhaler device studies Year: 2019 QVAR pMDI is more cost effective than CFC-beclometasone dipropionate (BDP) pMDI in a real-life asthmatic population initiating ICS Source: Annual Congress 2009 - Sustainability in treatment of COPD patients according to economics and quality of care Year: 2009 Mometasone furoate delivered via the Breezhaler® and Twisthaler® devices in asthma Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Budesonide/formoterol in a single inhaler sustains lung-function improvements in COPD Source: Eur Respir J 2003; 22: Suppl. 45, 50s Year: 2003 Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Flutide™ Diskus™ less consistent than Pulmicort® Turbuhaler® with respect to in vitro fine particle dose proportionality Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001 Transition to extra-fine formulation of inhaled beclomethasone/formoterol improves clinical and functional parameters in controlled and partly controlled asthmatics Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010